| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Vincenzo Di Marzo | Q29642556 |
| P2860 | cites work | Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in | Q80656570 |
| Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice | Q80735083 | ||
| The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms | Q81038508 | ||
| Allergic contact dermatitis and the endocannabinoid system: from mechanisms to skin care | Q81294620 | ||
| CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis | Q83820609 | ||
| Peripheral cannabinoid receptor, CB2, regulates bone mass | Q24536360 | ||
| CB2 receptor-mediated migration of immune cells: it can go either way | Q24643591 | ||
| The endocannabinoid system as an emerging target of pharmacotherapy | Q24648473 | ||
| A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol | Q24649418 | ||
| The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset | Q24650098 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Cannabinoid pharmacology: the first 66 years | Q24670395 | ||
| Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro | Q24673383 | ||
| Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats | Q24673420 | ||
| AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain | Q24675554 | ||
| Endocannabinoid signalling in the blood of patients with schizophrenia | Q24800061 | ||
| Endocannabinoids control spasticity in a multiple sclerosis model | Q28142626 | ||
| Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system | Q28182188 | ||
| The endocannabinoid system and gut-brain signalling. | Q36955435 | ||
| Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders | Q36969492 | ||
| The endocannabinoid system and extinction learning | Q36977769 | ||
| The endogenous cannabinoid system protects against colonic inflammation | Q37370275 | ||
| Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon | Q37371891 | ||
| Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension | Q37373710 | ||
| Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms | Q38757749 | ||
| Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve | Q39366176 | ||
| Multiple pathways involved in the biosynthesis of anandamide | Q40106992 | ||
| Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation | Q40142412 | ||
| Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors | Q40174517 | ||
| Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets | Q40184192 | ||
| The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism | Q40258566 | ||
| Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia | Q40282032 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. | Q40440754 | ||
| Further evidence for the existence of a specific process for the membrane transport of anandamide | Q40589014 | ||
| AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide | Q40654914 | ||
| The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors | Q41584525 | ||
| Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. | Q41604550 | ||
| Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors | Q41832173 | ||
| The endocannabinoid system controls key epileptogenic circuits in the hippocampus | Q42065383 | ||
| Rimonabant: more than an anti-obesity drug? | Q42111236 | ||
| Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats | Q42200119 | ||
| Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk | Q42287164 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats | Q42604006 | ||
| Endocannabinoid overactivity and intestinal inflammation | Q42844245 | ||
| Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol | Q42981075 | ||
| Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors | Q43004564 | ||
| Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents | Q43263256 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis | Q43658822 | ||
| Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. | Q43672168 | ||
| A cannabinoid mechanism in relapse to cocaine seeking. | Q43759232 | ||
| The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats | Q44254968 | ||
| Novel selective and metabolically stable inhibitors of anandamide cellular uptake | Q44430771 | ||
| Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response | Q44434119 | ||
| Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors | Q44443061 | ||
| Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain | Q44546972 | ||
| Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin | Q44594642 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade | Q44604752 | ||
| Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. | Q44719973 | ||
| In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake | Q44743034 | ||
| Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. | Q44770106 | ||
| Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function | Q44793025 | ||
| Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity | Q44903331 | ||
| Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality | Q44926848 | ||
| Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors | Q45003357 | ||
| Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). | Q45006435 | ||
| Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis | Q45032434 | ||
| Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 | ||
| Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. | Q45173372 | ||
| Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. | Q45188902 | ||
| Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear | Q45215137 | ||
| The anti-obesity effect of rimonabant is associated with an improved serum lipid profile | Q45218159 | ||
| Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents | Q45251047 | ||
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. | Q45297533 | ||
| Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. | Q45304520 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| Antifibrogenic role of the cannabinoid receptor CB2 in the liver | Q46376137 | ||
| Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa | Q46446318 | ||
| Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats | Q46471752 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test | Q46510119 | ||
| Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew | Q46514836 | ||
| Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes | Q46564021 | ||
| Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains | Q28189423 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Leptin-regulated endocannabinoids are involved in maintaining food intake | Q28211969 | ||
| Identification of GPR55 as a lysophosphatidylinositol receptor | Q28244299 | ||
| Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity | Q28253977 | ||
| Identification of a high-affinity binding site involved in the transport of endocannabinoids | Q28284073 | ||
| The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice | Q28296777 | ||
| The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation | Q28594581 | ||
| Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 | ||
| Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation | Q30478061 | ||
| Discovering potent and selective reversible inhibitors of enzymes in complex proteomes | Q31141832 | ||
| Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program | Q31144410 | ||
| The anandamide transport inhibitor AM404 activates vanilloid receptors. | Q31384563 | ||
| CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats | Q33289034 | ||
| CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health | Q33293362 | ||
| Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 | ||
| Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity | Q33921608 | ||
| Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents | Q34002682 | ||
| Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis | Q34234907 | ||
| SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization | Q34319264 | ||
| Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. | Q34320147 | ||
| A new strategy to block tumor growth by inhibiting endocannabinoid inactivation | Q34338108 | ||
| Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats | Q34374106 | ||
| Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 | ||
| An endocannabinoid mechanism for stress-induced analgesia. | Q34428429 | ||
| Functional role of high-affinity anandamide transport, as revealed by selective inhibition | Q34436019 | ||
| Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. | Q34449770 | ||
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial | Q34494637 | ||
| Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors | Q34520133 | ||
| Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors | Q34532228 | ||
| AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis | Q34539350 | ||
| Cannabinoids: potential anticancer agents | Q34542671 | ||
| The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases | Q34550883 | ||
| Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study | Q34556870 | ||
| A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol | Q34561595 | ||
| Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection | Q34597537 | ||
| Attenuation of allergic contact dermatitis through the endocannabinoid system | Q34635629 | ||
| Prostamides (prostaglandin-ethanolamides) and their pharmacology | Q34667670 | ||
| Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression | Q34673005 | ||
| Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids | Q34746098 | ||
| CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat | Q35047694 | ||
| New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis | Q35098586 | ||
| Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models | Q35545219 | ||
| Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. | Q35600288 | ||
| The endocannabinoid system and its therapeutic exploitation | Q35876026 | ||
| Cannabinoid-based drugs as anti-inflammatory therapeutics | Q36111923 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats | Q36357902 | ||
| Receptor-independent effects of endocannabinoids on ion channels | Q36384918 | ||
| Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists | Q36416335 | ||
| Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats | Q36426811 | ||
| Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury | Q36431793 | ||
| Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors | Q36447081 | ||
| Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase | Q36470347 | ||
| Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice | Q36496715 | ||
| Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). | Q36533477 | ||
| Endocannabinoids and the control of energy balance | Q36671574 | ||
| In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission | Q36686455 | ||
| Endocannabinoid mechanisms of pain modulation | Q36711160 | ||
| Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases | Q36734955 | ||
| Biochemistry and pharmacology of endovanilloids | Q36756199 | ||
| Endocannabinoids and the regulation of their levels in health and disease | Q36758111 | ||
| Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain | Q36912778 | ||
| The complications of promiscuity: endocannabinoid action and metabolism | Q36944706 | ||
| Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. | Q46667879 | ||
| Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla | Q46675581 | ||
| Fatty acid amide hydrolase controls mouse intestinal motility in vivo | Q46687826 | ||
| Anxiolytic-like properties of the anandamide transport inhibitor AM404. | Q46689323 | ||
| Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons | Q46730963 | ||
| Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 | ||
| Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis | Q46768353 | ||
| A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo | Q46781687 | ||
| Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ | Q46801175 | ||
| Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia | Q46807918 | ||
| Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis | Q46882914 | ||
| Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation | Q46887706 | ||
| Development of the first potent and specific inhibitors of endocannabinoid biosynthesis | Q46934838 | ||
| Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference | Q46947462 | ||
| Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex | Q46962183 | ||
| Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats | Q46991382 | ||
| The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis | Q48108020 | ||
| Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence | Q48148192 | ||
| Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret | Q48188856 | ||
| Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice | Q48298650 | ||
| The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport | Q48315882 | ||
| Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours | Q48387010 | ||
| Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats | Q48408629 | ||
| Effects of endocannabinoid neurotransmission modulators on brain stimulation reward | Q48428879 | ||
| Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats | Q48485540 | ||
| Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels | Q48518739 | ||
| Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. | Q48532776 | ||
| Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice | Q48600690 | ||
| Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase | Q48789988 | ||
| Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling | Q50113929 | ||
| Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. | Q50890840 | ||
| Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. | Q50933420 | ||
| Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. | Q51742983 | ||
| Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. | Q52001605 | ||
| Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597). | Q53577604 | ||
| Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity | Q60155177 | ||
| Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study | Q60209721 | ||
| Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain | Q60679661 | ||
| A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats | Q60690596 | ||
| Cannabinoids hurt, heal in cirrhosis | Q61456094 | ||
| Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells | Q61479730 | ||
| Involvement of the Endocannabinoid System in Retinal Damage after High Intraocular Pressure–Induced Ischemia in Rats | Q61896991 | ||
| Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice | Q79401094 | ||
| Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease | Q79802329 | ||
| Novel inhibitors of fatty acid amide hydrolase | Q80218012 | ||
| Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats | Q80383157 | ||
| The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level | Q80392594 | ||
| Cannabinoids and cardiovascular disease: the outlook for clinical treatments | Q80603691 | ||
| Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys | Q80609691 | ||
| P433 | issue | 5 | |
| P921 | main subject | endocannabinoid system | Q368952 |
| P304 | page(s) | 438-455 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Targeting the endocannabinoid system: to enhance or reduce? | |
| P478 | volume | 7 |
| Q27015753 | "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control |
| Q43213315 | 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies. |
| Q34141083 | A Common Haplotype in NAPEPLD Is Associated With Severe Obesity in a Norwegian Population‐Based Cohort (the HUNT Study) |
| Q30396103 | A Treasure Trove of Hypothalamic Neurocircuitries Governing Body Weight Homeostasis |
| Q35633097 | A catalytically silent FAAH-1 variant drives anandamide transport in neurons |
| Q42017075 | A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist |
| Q33885350 | A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor |
| Q41897358 | A natural substrate-based fluorescence assay for inhibitor screening on diacylglycerol lipase α. |
| Q36176499 | A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury |
| Q36943231 | A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects |
| Q48941763 | A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice |
| Q34467166 | A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo |
| Q36795697 | Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. |
| Q82213638 | Analgesics: Pain control at the periphery |
| Q43236175 | Anandamide extends platelets survival through CB(1)-dependent Akt signaling |
| Q39835267 | Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation |
| Q34856974 | Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. |
| Q37630381 | Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus) |
| Q43190361 | Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action? |
| Q46170516 | Anti-inflammatory effect of palmitoylethanolamide on human adipocytes |
| Q87958145 | Anticonvulsive effects of endocannabinoids; an investigation to determine the role of regulatory components of endocannabinoid metabolism in the Pentylenetetrazol induced tonic- clonic seizures |
| Q37710345 | Antihyperalgesic Activities of Endocannabinoids in a Mouse Model of Antiretroviral-Induced Neuropathic Pain |
| Q34801735 | Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms |
| Q33684510 | Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase |
| Q27005619 | Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review |
| Q54443602 | Assay of DAGLα/β Activity. |
| Q41271075 | Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study |
| Q33960806 | Association of the c.385C>A (p.Pro129Thr) polymorphism of the fatty acid amide hydrolase gene with anorexia nervosa in the Japanese population |
| Q88052513 | Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase |
| Q42141502 | Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH) |
| Q49679435 | Bioactive Lipids and Chronic Inflammation: Managing the Fire Within |
| Q34165188 | Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol |
| Q41785885 | Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability |
| Q34251969 | Blurred boundaries: the therapeutics and politics of medical marijuana |
| Q37160279 | CB1 cannabinoid receptor inhibition: promising approach for heart failure? |
| Q34098258 | CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model |
| Q35230062 | CB2 cannabinoid receptor targets mitogenic Gi protein–cyclin D1 axis in osteoblasts |
| Q33488512 | CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis |
| Q34117612 | Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes |
| Q43289886 | Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis |
| Q34948216 | Cannabidiol: a promising drug for neurodegenerative disorders? |
| Q39021787 | Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation? |
| Q35766956 | Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy |
| Q38754663 | Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia. |
| Q43145354 | Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? |
| Q37105857 | Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation |
| Q33464957 | Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis |
| Q39877226 | Cannabinoid Receptor 1 Mediates Homing of Bone Marrow-Derived Mesenchymal Stem Cells Triggered by Chronic Liver Injury |
| Q47406095 | Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling |
| Q55252194 | Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. |
| Q37553341 | Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease |
| Q33750632 | Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. |
| Q33889311 | Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice |
| Q37568626 | Cannabinoid receptor CB1 antagonists state of the art and challenges. |
| Q37546194 | Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? |
| Q46132299 | Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. |
| Q34402180 | Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies |
| Q34098271 | Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells |
| Q34992139 | Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions |
| Q33847549 | Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38971616 | Cannabinoids and GI Disorders: Endogenous and Exogenous |
| Q91934280 | Cannabinoids and the expanded endocannabinoid system in neurological disorders |
| Q38918638 | Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? |
| Q34049715 | Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. |
| Q95841072 | Cannabinomics: Application of Metabolomics in Cannabis (Cannabis sativa L.) Research and Development |
| Q89510317 | Cannabis Sativa Revisited-Crosstalk between microRNA Expression, Inflammation, Oxidative Stress, and Endocannabinoid Response System in Critically Ill Patients with Sepsis |
| Q50066240 | Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences |
| Q37826693 | Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation |
| Q37428727 | Capturing adenylyl cyclases as potential drug targets |
| Q33865109 | Carboxylesterases: Dual roles in lipid and pesticide metabolism |
| Q47804552 | Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly |
| Q38292488 | Cerebellar endocannabinoids: retrograde signaling from purkinje cells. |
| Q26863202 | Chemical probes of endocannabinoid metabolism |
| Q34557589 | Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake |
| Q34635002 | Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer |
| Q36922992 | Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men |
| Q43502703 | Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study |
| Q36403320 | Comprehensive Analysis of Structure-Activity Relationships of α-Ketoheterocycles as sn-1-Diacylglycerol Lipase α Inhibitors |
| Q24324741 | Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling |
| Q37788467 | DAG Lipase Involvement in Depolarization-Induced Suppression of Inhibition: Does Endocannabinoid Biosynthesis Always Meet the Demand? |
| Q41923080 | Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH). |
| Q47149284 | Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice |
| Q38911315 | Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection |
| Q86825974 | Delineation of domains within the cannabinoid CB1 and dopamine D2 receptors that mediate the formation of the heterodimer complex |
| Q42156717 | Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase |
| Q58753616 | Development of a Multiplexed Activity-Based Protein Profiling Assay to Evaluate Activity of Endocannabinoid Hydrolase Inhibitors |
| Q34243225 | Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). |
| Q90080135 | Different Routes to Inhibit Fatty Acid Amide Hydrolase: Do All Roads Lead to the Same Place? |
| Q36990238 | Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats. |
| Q53105853 | Differential effects of endogenous, phyto and synthetic cannabinoids on thrombogenesis and platelet activity. |
| Q34582707 | Discovery of GPCR ligands for probing signal transduction pathways |
| Q89684024 | Discovery of Selective Cannabinoid CB2 Receptor Agonists by High-Throughput Screening |
| Q38874824 | Dissecting the Signaling Pathways Involved in the Crosstalk between Metabotropic Glutamate 5 and Cannabinoid Type 1 Receptors |
| Q39288073 | Dissociation of within- and between-session extinction of conditioned fear |
| Q44291714 | Distance measurements and conformational analysis of sn-2-arachidonoylglycerol-membrane sample by ²H-³¹P REDOR NMR |
| Q36417706 | Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease |
| Q39635515 | Dual Neuroprotective and Neurotoxic Effects of Cannabinoid Drugs in Vitro |
| Q42167232 | Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients |
| Q28572239 | Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling |
| Q35585455 | Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation |
| Q28300390 | Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications |
| Q37230665 | Emerging strategies for exploiting cannabinoid receptor agonists as medicines |
| Q57024413 | Endocannabinoid Virodhamine is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase |
| Q33997873 | Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown |
| Q37308316 | Endocannabinoid crosstalk between placenta and maternal fat in a baboon model (Papio spp.) of obesity |
| Q28551031 | Endocannabinoid dynamics gate spike-timing dependent depression and potentiation |
| Q34953319 | Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey |
| Q37250243 | Endocannabinoid signaling in microglial cells |
| Q60690528 | Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight |
| Q35754490 | Endocannabinoid signalling and the deteriorating brain |
| Q83728202 | Endocannabinoid system protects against cryptogenic seizures |
| Q55452539 | Endocannabinoids and Schizophrenia. |
| Q43290095 | Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. |
| Q37401757 | Endocannabinoids and cardiac contractile function: pathophysiological implications |
| Q35255737 | Endocannabinoids and inflammatory response in periodontal ligament cells. |
| Q33583792 | Endocannabinoids and striatal function: implications for addiction-related behaviours |
| Q36395277 | Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. |
| Q38931168 | Endocannabinoids in the gastrointestinal tract |
| Q46783271 | Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. |
| Q39362682 | Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells |
| Q37648343 | Endocannabinoids: A Promising Impact for Traumatic Brain Injury. |
| Q27009220 | Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations |
| Q27308091 | Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments |
| Q43180981 | Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system |
| Q37186197 | Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors |
| Q27325738 | Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain |
| Q36298487 | Evidence for bidirectional endocannabinoid transport across cell membranes |
| Q41763884 | Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer |
| Q34461780 | FAAH selectively influences placebo effects |
| Q28285103 | Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders |
| Q28267884 | Fatty acid amide hydrolase inhibitors: a patent review (2009-2014) |
| Q90638345 | From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases |
| Q39610927 | Functional characterization of putative cholesterol binding sequence (CRAC) in human type-1 cannabinoid receptor |
| Q38220272 | Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier |
| Q33468429 | Genetic manipulation of palmitoylethanolamide production and inactivation in Saccharomyces cerevisiae |
| Q39761953 | Gut feelings about the endocannabinoid system |
| Q82691763 | Hepatic steatosis and endocannabinoids--does it all happen within the liver? |
| Q39485775 | Heterologous regulation of the cannabinoid type 1 receptor by angiotensin II in astrocytes of spontaneously hypertensive rats |
| Q36131752 | High-Intensity Swimming Exercise Decreases Glutamate-Induced Nociception by Activation of G-Protein-Coupled Receptors Inhibiting Phosphorylated Protein Kinase A. |
| Q38713130 | Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons |
| Q35992150 | Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates |
| Q43108843 | Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle |
| Q47701321 | Human serum albumin: A modulator of cannabinoid drugs |
| Q51751156 | Hydroxyalkylation with cyclic sulfates: synthesis of carbazole derived CB(2) ligands with increased polarity. |
| Q30561814 | Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors |
| Q24658373 | Identification of intracellular carriers for the endocannabinoid anandamide |
| Q37637750 | In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. |
| Q30981876 | Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2 |
| Q37680661 | Inflammatory lipid mediators in adipocyte function and obesity. |
| Q37998313 | Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain |
| Q39596907 | Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB(1) receptors: a keratinocyte-dependent effect |
| Q54273247 | Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. |
| Q28082891 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants |
| Q92359782 | Inhibitory Control Deficits Associated with Upregulation of CB1R in the HIV-1 Tat Transgenic Mouse Model of Hand |
| Q28258759 | Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice |
| Q28066215 | Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation |
| Q38686274 | Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives |
| Q35310056 | Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide |
| Q41662155 | Involvement of TRPV1 channels in the periaqueductal grey on the modulation of innate fear responses |
| Q41693823 | Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in rats |
| Q24633122 | Is lipid signaling through cannabinoid 2 receptors part of a protective system? |
| Q34521105 | Keep off the grass? Cannabis, cognition and addiction |
| Q35655078 | Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. |
| Q28287173 | Latest advances in the discovery of fatty acid amide hydrolase inhibitors |
| Q37295577 | Lipidomic analysis of endocannabinoid metabolism in biological samples. |
| Q60690548 | Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics |
| Q39938122 | Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. |
| Q36485174 | Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation |
| Q41965347 | Localization of diacylglycerol lipase alpha and monoacylglycerol lipase during postnatal development of the rat retina |
| Q52842340 | Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. |
| Q34173626 | Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? |
| Q37108375 | Marine cyanobacterial fatty acid amides acting on cannabinoid receptors. |
| Q58102489 | Medical Use of Cannabinoids |
| Q34308885 | Medical use of cannabis. Cannabidiol: a new light for schizophrenia? |
| Q39174710 | Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy |
| Q36947747 | Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes |
| Q39333722 | Metabolism of anandamide into eoxamides by 15-lipoxygenase-1 and glutathione transferases. |
| Q21093231 | Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors? |
| Q34363783 | Microwave Assisted Synthesis of Sodium Sulfonates Precursors of Sulfonyl Chlorides and Fluorides |
| Q36956632 | Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. |
| Q36933683 | Modulating the endocannabinoid system in human health and disease--successes and failures |
| Q38830313 | Modulation of Calcium Entry by the Endo-lysosomal System |
| Q38056397 | Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system |
| Q90322108 | Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues |
| Q41140010 | Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model |
| Q36940347 | Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations |
| Q37568637 | Modulation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase by follicle-stimulating hormone. |
| Q48020118 | Molecular Dynamics Methodologies for Probing Cannabinoid Ligand/Receptor Interaction |
| Q41862863 | Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT. |
| Q35778735 | Molecular and cellular pathways as a target of therapeutic hypothermia: pharmacological aspect |
| Q33588600 | Motion sickness, stress and the endocannabinoid system |
| Q48000929 | Mouse retinal ganglion cell signalling is dynamically modulated through parallel anterograde activation of cannabinoid and vanilloid pathways. |
| Q61479726 | Moving bliss: a new anandamide transporter |
| Q34104073 | Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism |
| Q50026271 | Neuroprotective Effects of MAGL (Monoacylglycerol Lipase) Inhibitors in Experimental Ischemic Stroke |
| Q38185067 | Neurotrophins, endocannabinoids and thermo-transient receptor potential: a threesome in pain signalling. |
| Q57165498 | New approaches and challenges to targeting the endocannabinoid system |
| Q90341504 | Novel Anti-inflammatory and Vasodilatory ω-3 Endocannabinoid Epoxide Regioisomers |
| Q36996148 | Novel adamantyl cannabinoids as CB1 receptor probes |
| Q38300166 | Novel investigational therapeutics for panic disorder |
| Q43213371 | O-(triazolyl)methyl carbamates as a novel and potent class of fatty acid amide hydrolase (FAAH) inhibitors. |
| Q41971391 | O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors |
| Q39904600 | Opposing roles for cannabinoid receptor type-1 (CB₁) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats |
| Q24657799 | Orphan endogenous lipids and orphan GPCRs: a good match |
| Q46042315 | Overactive type 2 cannabinoid receptor induces meiosis in fetal gonads and impairs ovarian reserve |
| Q91717872 | Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development |
| Q48577676 | Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice |
| Q33714587 | Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications |
| Q34473739 | PET imaging of fatty acid amide hydrolase with [(18)F]DOPP in nonhuman primates |
| Q42155237 | PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2. |
| Q92450435 | Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice |
| Q47162113 | Peripheral Endocannabinoid Responses to Hedonic Eating in Binge-Eating Disorder |
| Q42921222 | Peripheral Endocannabinoid System‐Mediated Actions of Rimonabant on Growth Hormone Secretion are Ghrelin‐Dependent |
| Q39324195 | Pharmacogenetics of Cannabinoids. |
| Q45585427 | Pharmacological characterization of the cannabinoid CB1 receptor PET ligand ortholog, [3H]MePPEP |
| Q47694616 | Photobiomodulation Therapy Improves Acute Inflammatory Response in Mice: the Role of Cannabinoid Receptors/ATP-Sensitive K(+) Channel/p38-MAPK Signalling Pathway |
| Q28286497 | Phytocannabinoids beyond the Cannabis plant - do they exist? |
| Q33993270 | Pitfalls and solutions in assaying anandamide transport in cells |
| Q37889127 | Plant volatiles: production, function and pharmacology |
| Q46434533 | Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? |
| Q33446413 | Possible Anandamide and Palmitoylethanolamide involvement in human stroke |
| Q37352175 | Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death |
| Q97884838 | Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options |
| Q33943990 | Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice |
| Q37872326 | Prospects for cannabinoid therapies in basal ganglia disorders |
| Q48132194 | Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. |
| Q38028659 | Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors |
| Q34718182 | Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats |
| Q38215702 | Regulation of adipocyte lipolysis |
| Q37568674 | Regulation of gene transcription and keratinocyte differentiation by anandamide |
| Q41998630 | Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? |
| Q90333182 | Relationship between body condition score loss and mRNA of genes related to fatty acid metabolism and the endocannabinoid system in adipose tissue of periparturient cows |
| Q60690490 | Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity |
| Q41008505 | Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease |
| Q42129431 | Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs |
| Q36404379 | Role of cannabinoids in the regulation of bone remodeling |
| Q34993855 | Role of cannabis and endocannabinoids in the genesis of schizophrenia |
| Q38672585 | Role of palmitoylation of cysteine 415 in functional coupling CB1 receptor to Gαi2 protein |
| Q35211715 | SIRT1 deacetylase in SF1 neurons protects against metabolic imbalance |
| Q45995000 | Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. |
| Q90193965 | Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis |
| Q37469677 | Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. |
| Q24569799 | Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects |
| Q30612936 | Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents |
| Q33716248 | Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. |
| Q28304230 | Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer |
| Q34023143 | Strategies for discovering and derisking covalent, irreversible enzyme inhibitors |
| Q28257042 | Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids |
| Q64866431 | Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases |
| Q43237260 | Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure |
| Q36970368 | Synthesis and Preclinical Evaluation of Sulfonamido-based [(11)C-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase |
| Q39876164 | Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol |
| Q34101852 | Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. |
| Q26823304 | TRPV1 and Endocannabinoids: Emerging Molecular Signals that Modulate Mammalian Vision |
| Q37553151 | Targeted lipidomics as a tool to investigate endocannabinoid function. |
| Q57174777 | Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models |
| Q37960078 | Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. |
| Q28386297 | Ten years of Nature Reviews Neuroscience: insights from the highly cited |
| Q35167301 | The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors |
| Q38566339 | The Endocannabinoid System and its Modulation by Phytocannabinoids |
| Q97530276 | The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? |
| Q48190647 | The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. |
| Q28267813 | The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review |
| Q37878270 | The Role of Phospholipase A(2)-derived Mediators in Obesity |
| Q35937792 | The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. |
| Q54612198 | The anandamide effect on NO/cGMP pathway in human platelets. |
| Q37395994 | The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. |
| Q34115272 | The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184 |
| Q36981186 | The dual effect of cannabinoid receptor-1 deficiency on the murine postoperative ileus |
| Q35193273 | The dual neuroprotective-neurotoxic profile of cannabinoid drugs |
| Q37439386 | The emerging role of the endocannabinoid system in cardiovascular disease |
| Q33790150 | The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels |
| Q38885661 | The endocannabinoid system - a target for the treatment of LUTS? |
| Q35193299 | The endocannabinoid system and cancer: therapeutic implication |
| Q34612917 | The endocannabinoid system and pain |
| Q37256886 | The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis |
| Q35193292 | The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings |
| Q28247621 | The endocannabinoid system as a potential therapeutic target for pain modulation |
| Q37520727 | The endocannabinoid system as a target for modelling psychosis |
| Q34992627 | The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs |
| Q37709370 | The endocannabinoid system as a target for the treatment of neuronal damage |
| Q48097673 | The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis |
| Q34787318 | The endocannabinoid system in obesity and type 2 diabetes. |
| Q34078880 | The endocannabinoid system links gut microbiota to adipogenesis |
| Q37375986 | The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities |
| Q35122796 | The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications |
| Q34660573 | The major central endocannabinoid directly acts at GABA(A) receptors |
| Q34393890 | The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease |
| Q37913717 | The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. |
| Q48512439 | The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents |
| Q24617322 | The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors |
| Q27678921 | The structure of monoacylglycerol lipase from Bacillus sp. H257 reveals unexpected conservation of the cap architecture between bacterial and human enzymes |
| Q36727793 | The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH). |
| Q28818633 | The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil |
| Q64975245 | Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients. |
| Q58775742 | Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis |
| Q35976725 | Transient receptor potential vanilloid type 1-dependent regulation of liver-related neurons in the paraventricular nucleus of the hypothalamus diminished in the type 1 diabetic mouse |
| Q38084704 | Transport of endocannabinoids across the plasma membrane and within the cell |
| Q84676146 | Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists |
| Q60686096 | Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo |
| Q34835434 | Unique pathway for anandamide synthesis and liver regeneration |
| Q34042152 | Unraveling the complex relationship triad between lipids, obesity, and inflammation |
Search more.